Market Definition
Autoimmune Disorder Drug Delivery Devices are specialized devices used for the delivery of drugs or therapeutic agents via a specific route of administration to treat immune system abnormalities in humans. The rise in autoimmune diseases caused by sedentary lifestyles or over activities has led to severe immune system disorders in today’s era. To selectively target immune cells in peripheral tissues or diseased tissues, the medical practitioners & government are enormously supporting huge R&D investments to focus on new approaches in drug delivery. This has led to an increase in the demand for autoimmune disorder drug delivery devices globally.
Market Insights
The Global Autoimmune Disorder Drug Delivery Devices Market is projected to grow at a CAGR of around 16.89% in terms of revenue during the forecast period, i.e., 2022-27. Increasing environmental triggers such as viruses & bacteria, use of chemical fertilizers, rising exposure to harmful ultraviolet rays, and nutritional deficiencies have resulted in the development of autoimmune diseases such as juvenile dermatomycosis & rheumatoid arthritis, among many others. According to the National Stem Cell Foundation (NCSF), globally, around 4% of the population is affected by one of more than 80 different types of autoimmune diseases.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR (2022-2027) | 16.89% |
| Regions Covered | North America: USA, Canada, Mexico |
| Europe: Germany, UK, Germany, France, Italy, Spain, Others | |
| Asia-Pacific: China, India, Japan, South Korea, Australia and Others | |
| South America: Brazil, and Others | |
| Middle East & Africa: UAE, Saudi Arabia, South Africa | |
| Key Companies Profiled | Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., The Merck Group, Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB Pharma SA |
| Unit Denominations | USD Million/Billion |
Moreover, the rising awareness among the regional governments to minimize the health risks associated with autoimmune diseases to control the fatality rates globally has driven the interest of medical practitioners to invest in R&D activities for the development of effective drug delivery systems & devices. In 2019, under the EU’s Innovative Medicine Initiative, the European Union-funded a USD89.61 million project named ‘Taxonomy, Treatments, Targets, and Remission, or 3TR'. The project aims to increase therapeutic success, reduce the risk of avoidable side effects in patients that are unlikely to benefit from the drugs prescribed, reduce the healthcare cost, and improve the quality of life.
Furthermore, heightening the adoption of advanced medical technologies in hospitals & households for effective drug deliveries & minimizing the impacts of medical side effects have portrayed enormous opportunities for autoimmune Disorder drug delivery devices globally.
Key Trends in the Market
Proliferating Trend Towards Self-Administration & Better Homecare to Support the Market Growth
A significant increase in the adoption of self-injectable devices for the treatment of autoimmunity disorders such as diabetes etc., combined with the rapid surge in hospital-acquired infections, high medical costs, and longer wait hauls, have accelerated the shift towards the use of autoimmune disorder drug delivery devices in households globally. Moreover, various companies such as Becton, Dickinson, and Insulet Corporation have launched self-injectable devices to bring economic benefits to both patients & healthcare systems. For instance, pressure-assisted auto-injectors by Antares Pharma are a form of parenteral drug delivery to address acute & chronic medical needs such as rheumatoid arthritis, allergic reactions, psoriasis, and other therapies.
Impact of Covid-19 on the Global Autoimmune Disorder Drug Delivery Devices Market
The outbreak of the Covid-19 pandemic made a relatively positive impact on the Global Autoimmune Disorder Drug Delivery Devices market The burgeoning requirement for drug delivery devices in hospitals & households to inject immunity boosters to COVID infected patients globally fueled the market demand for drug delivery devices. According to the National Institute for Health Research, 'the spread of SARS-COV-2 has created long-term autoimmune complications, including the Guillain-Barre-Syndrome, which has spurred the demand for the development of autoimmune disorder drug delivery devices for enhanced patient recoveries in the global markets.
Further, the healthcare & medical sectors experienced robust growth amidst the pandemic, despite the severe effects on nearly every industry worldwide. Moreover, with the increasing spread of the virus, the need for Drug Delivery Devices has been propelling exponentially. Still, the market had to face slight delays & limitations because of the imposition of lockdown & restrictions on logistics. However, the manufacturing of the devices is expanding robustly. Furthermore, with the gradual upliftment of lockdown & ease of norms, the Global Autoimmune Disorder Drug Delivery Devices market shall increase its production & supply and experience rapid growth in the coming years.
